Effective April 2, 2025, all screeners previously provided by Sivadata Pty Ltd have been transferred to Kalkine Pty Ltd, a related entity of Sivadata Pty Ltd. You can access these screeners via the link https://kalkine.com.au/screeners.
Stock Market

Abercrombie & Fitch started at neutral as 'uncertain times prevail'

Investing | Tue, Apr 22 2025 01:53 AM AEST

1695367561_650d4189d32c8_1692951951_64e8658fe70f4_breaking_news_600.png
Image Source: Sivastatz
Abercrombie & Fitch started at neutral as 'uncertain times prevail'

Investing.com -- Barclays initiated coverage of Abercrombie&Fitch with an Equal Weight rating and a $71 price target on Monday.

The bank told investors it balanced the company’s strong recent performance and brand momentum against a backdrop of potential margin pressure and sector-wide uncertainty.

“Our rating balances our view of ANF’s strong brand heat, best-in-class omnichannel model, and future store growth opportunities against risks from elevated inventory levels, potentially peaking margins, higher marketing spending, difficult compares in FY25, and sector-wide tariff uncertainty,” Barclays (LON:BARC) wrote in a note initiating coverage.

The analysts pointed to robust recent growth, with Abercrombie delivering consolidated comp sales growth of 13 percent and 17 percent in fiscal 2023 and 2024, respectively.

“Management expects FY25 to be another year of revenue growth across brands and regions,” Barclays said, highlighting Abercrombie’s “durable and sizable growth across regions” and a five-year net revenue CAGR of 12 percent versus 2 percent for Hollister.

The analysts also praised the company’s omnichannel capabilities, calling it a “highly-profitable, high-penetration digital business” complemented by “store four-wall margins of ~30%.”

New store experiences and expansion through wholesale, franchise, and licensing were seen as long-term growth drivers.

Still, Barclays flagged several near-term headwinds. “Elevated inventory levels exiting FY24, with higher seasonal carryover, [are] expected to pressure gross margins,” they wrote.

The firm also cited rising freight costs, higher marketing spend, and tough year-over-year comparisons, especially as Abercrombie laps a 29 percent comp in the first quarter of FY24. Early trends in FY1Q25 comps are already “running ‘a bit negative,’” as of March 5.

Barclays also noted ongoing industry-wide concerns: “sector-wide tariff uncertainty” adds a further layer of risk, limiting visibility for fiscal 2025.

As a result, the firm concluded, “uncertain times prevail” and the stock is best viewed with a neutral stance for now.

This article first appeared in Investing.com

Market Updates

Apromore Recognized as a Leader in 2025 Gartner® Magic Quadrant™ for Process Mining Platforms for Third Consecutive Year

MELBOURNE, Australia & NEW YORK--(BUSINESS WIRE)--#AI--Apromore, a global leader in process mining and process intelligence technology, has been ...

Business Wire | Tue, Apr 22 2025 06:56 AM AEST

Read More
World News

AEG Presents Hosts Career Exposure Day for High School Students During Coachella Valley Music and Arts Festival

On April 16, 2025, 125 high school students in Indio, CA, were treated to a behind the scenes look of the iconic Coachella ...

3BL | Tue, Apr 22 2025 05:05 AM AEST

Read More
Stock Market

Morgan Stanley cuts Warner Music Group rating on 'more balanced risk/reward'

Investing.com -- Morgan Stanley downgraded Warner Music Group (NASDAQ:WMG) shares to Equal-weight from Overweight and cut its price ...

Investing | Tue, Apr 22 2025 04:39 AM AEST

Read More
Stock Market

TD Cowen upgrades Fidelity National to 'Buy' on cleaner model, macro resilience

Investing.com -- TD Cowen upgraded Fidelity National Information Services (NASDAQ:III) to “Buy” from “Hold” raising its price target ...

Investing | Tue, Apr 22 2025 03:31 AM AEST

Read More
Market Updates

Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive NMIBC Patients1

First results from a Phase 3 trial conducted across 25 centers in Japan were presented at the Annual Meeting of the Japanese ...

Business Wire | Tue, Apr 22 2025 03:30 AM AEST

Read More